Ariad Pharmaceuticals Inc.

Plus: Maslowski to become CEO of Forge as Miller steps down, and updates from Sofinnova Partners, Abingworth, PATH and more

Select committee requests Justice Department investigation of BIO

Plus: Morphic’s CEO Tipirneni returns and more from Kojin, Harvard, Star, Novavax, Entrada, Brii, Switch, SmartCella

Plus: Cameron Turtle becomes CEO of Spyre, and updates from Ocuphire and Astraveus

Plus: Theseus readies for IPO, Oxitope launches, Allay, MiMedx, Roche-Temedica

The acquisition fits squarely in Takeda’s transformation from a small molecule company to one built on multiple modalities. 

Gene therapy developer Freeline Therapeutics Holdings plc (NASDAQ:FRLN) hired Mark Baldry as chief commercial officer. He previously held the same role at Wave Life Sciences Ltd. (NASDAQ:WVE). 

A look at Takeda's deals shows the pharma is increasingly embracing edgier technologies

How preclinical POC on Akrevia’s tumor-activated therapies enabled its $30M series A